ASCO GU 2026 Day One Update: Advancements in Prostate Cancer Treatment

Yesterday marked day one of the 2026 ASCO Genitourinary (GU) Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies that are especially exciting for patients: the phase 3 EORTC 1333/PEACE-3 trial which evaluated the combination of Xtandi (enzalutamide) and Xofigo (radium-223), and the phase 3 CAPItello-281 trial which evaluated pairing of Truqap (capivasertib) with Zytiga (abiraterone) in PTEN-deficient disease.

First, the Xtandi plus Xofigo study focused on men with metastatic castration-resistant prostate cancer that had spread to the bones. The results showed that combining these two therapies could help patients live longer. What makes this particularly meaningful is that the benefit wasn’t short-lived—patients maintained their improved outcomes over time. “The combination of Xtandi and Xofigo demonstrated a significant survival benefit,” researchers noted, confirming that pairing these treatments works better than Xtandi alone for some patients. Importantly, the treatment was manageable, with side effects that doctors felt could be monitored and treated.

Next, the Truqap plus Zytiga study looked at men with PTEN-deficient metastatic hormone-sensitive prostate cancer, a genetic feature that can make the disease more aggressive. The study found that adding Truqap to Zytiga helped control the cancer without meaningfully lowering quality of life. Patients maintained their ability to do daily activities and experienced minimal additional side effects, making this a treatment option that not only targets the cancer but also preserves everyday functioning.

Taken together, these studies highlight two critical trends in prostate cancer care: treatments are helping patients live longer, and researchers are increasingly focused on how patients feel while receiving therapy. For men with advanced prostate cancer, these findings offer hope and real progress in managing their disease.

CURE will continue following updates throughout the ASCO GU meeting, breaking down what these results mean for real-world patient care and treatment decisions.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.